The women’s health and wellness space is booming. The opportunities are real and so are the rewards. This is where you keep up. Welcome to The DXF Edit.
This Week’s Hot Topics:
- AI is bringing the first objective standard to egg quality assessment in IVF.
- A Barcelona startup is building the first sex-specific biological atlas of the female body from a single blood test.
- A new wrist-worn wearable is inferring hormonal patterns continuously, no blood draws required.
- The most common form of abortion just got a nationwide barrier, with no new safety data and no congressional vote.
- Soft life vs. grind: the wellness war playing out on your feed has a better answer than either side is offering.
MONEY MOVES
IVF Has Always Needed an Objective Standard for Egg Quality. Future Fertility Is Building It.
Embryologists have always assessed egg quality by eye. No standardized scale. No objective data. Just years of training, a microscope, and a judgment call that can cost a woman $20,000 and months of her life if it goes wrong.
Future Fertility is replacing that guesswork with AI. The Toronto-based company just closed a $4.1M Series A to scale its deep learning tools, trained on 650,000+ oocyte images and already deployed in 300+ clinics across 35 countries. The suite covers egg freezing, IVF, and donor programs. ROSE, its donor egg tool, is already available in the U.S. Clearance for the IVF and egg freezing products is the next move.
IVF is one of the most physically and financially demanding things a woman can put her body through. Multiple rounds of hormonal stimulation, retrievals, and transfers. Each cycle costs anywhere from $15,000 to $30,000, with no guarantees. Women deserve better odds on that investment. Better egg quality assessment means better clinical decisions at every stage of the process, including which cycle to pursue, which eggs to prioritize, when to stop, and when to keep going. With women having children later in life, this has the potential to save thousands of women from having to go through multiple rounds of IVF for a single successful pregnancy.
Medicine Has Been Studying the Wrong Body for Decades. One Startup Is Fixing That.
Women are diagnosed four years later than men across more than 700 diseases. Most AI models in medicine are trained on male data. The diagnostic tools, reference ranges, and treatment protocols that define modern medicine were built around a body that isn’t women’s. But women are NOT ‘little men’!
Barcelona-based BASE4 Biosciences just raised a $1M pre-seed to build what should have existed decades ago: a sex-specific biological atlas of the female body from a single blood test. The platform analyzes 15,000+ genes and 330 metabolic pathways across 47 tissues, detecting molecular decline before symptoms appear and before conventional diagnostics catch anything.
The focus areas are exactly where medicine’s gender gap does the most damage: ovarian biology, menopause-related changes, early fertility decline. Ovarian tissue ages five times faster than other body tissues. Over 75% of IVF cycles fail in women over 35. BASE4 is building the infrastructure to change what’s possible in those spaces and more.
INNOVATION
Continuous Hormone Tracking, Without Blood? Clair Got Our Attention.
Clair is a wrist-worn wearable that infers hormonal patterns continuously without blood draws, or lab visits. Ten biosensors read physiological signals like heart rate variability, skin temperature, sleep, and breathing rate, then AI translates them into hormonal insight across cycle phases, fertility windows, and perimenopause transitions.
The use cases are broad: confirming ovulation actually happened (not just that the LH surge occurred), surfacing the hormonal context behind symptoms fitness trackers ignore, and mapping how cycle phase affects training and recovery. Early testing across 40 women and 127 cycles showed 94.1% accuracy in cycle phase classification and 87% LH surge detection sensitivity. Stanford Medicine clinical trial launching this spring. Device ships November 2026, pre-orders are open.
Clair infers hormones from physiological signals; it doesn’t measure them directly. The device shows patterns and phases for now, not precise hormone values. For now, we remain skeptical but very curious to see how this impacts women who struggle with hormonal issues and those who are trying to conceive.
Women Didn’t Trust AI With Their Health. So Peanut Built Something Better.
Forty million people ask health questions to AI every day. And a growing number of them, especially women navigating pregnancy, fertility, and early motherhood, immediately take those answers to their communities to check if they’re actually right. Since February 2025, Peanut has seen a 2,041% increase in users posting ChatGPT responses into the app, asking other moms to verify them. Women don’t trust AI alone. They want human validation.
So Peanut built an app around that behavior instead of fighting it. Ask Peanut searches millions of community conversations, synthesizes the relevant insights, drafts a post on the user’s behalf, and recommends the best communities to share it in for real human responses. The AI is trained on Peanut’s own community data so it’s grounded in real women’s experiences from the start. Then it hands the conversation back to the community. The AI is the on-ramp. The community is the destination.
2,041% growth in women fact-checking AI with each other is not a bug. It’s a design brief.
LAW & POLICY
The Abortion Pill Just Became a Supreme Court Emergency. Again.
On May 1, the 5th Circuit Court of Appeals reinstated the requirement that mifepristone be obtained in person, ending telehealth prescriptions and mail distribution nationwide. No new safety data. No congressional vote. Just a court order that immediately upended access to the most common form of abortion in the country for the roughly 27% of women who obtain it via telehealth.
The chaos lasted 72 hours. By May 4, the Supreme Court issued a temporary administrative stay, blocking the 5th Circuit ruling until May 11 at 5pm ET while it reviews emergency appeals filed by mifepristone manufacturers Danco Laboratories and GenBioPro. Justice Samuel Alito, who handles emergency requests from the 5th Circuit, issued the order.
The stay is not a ruling. It is not a win. It is a pause button with a hard deadline — and a Supreme Court that has already overturned Roe now deciding what happens next. Meanwhile providers are in limbo, patients are confused, and telehealth organizations operating under shield laws are still working with legal teams to understand what they can and cannot do. As one reproductive rights legal scholar put it: “Fewer people are going to use telehealth until this is sorted out — because they’re not going to know if they can.” That chilling effect is intentional.
May 11 is the next deadline.
The Word “Women” Is Now Enough to Kill a Research Grant.
A Washington Post analysis found a 31% decline in NIH grants containing the word “women” in 2025. Not controversial research. Not wasteful spending. Grants that used the word “women.” At a Senate hearing on April 22, Senator Collins confronted RFK Jr. directly: “I still think we have a problem if grants are being scanned for the word ‘women’ and then clawed back or not funded.” Kennedy did not deny it.
The damage lands on research that was already critically underfunded. A congressionally mandated NASEM report found that only 8.8% of NIH research spending from 2013 to 2023 targeted women’s health, despite women making up more than half of the U.S. population. Conditions like endometriosis, fibroids, and PCOS affect millions of women and remain chronically underfunded relative to their disease burden. The cuts aren’t disrupting a thriving research ecosystem. They’re accelerating a decades-long gap.
When NIH cancelled nearly 2,300 grants last year, the $2.5 billion in terminated funding translated to an estimated $6.3 billion in unrealized economic output. Researchers studying endometriosis, menopause, and maternal mortality are watching their labs go dark, work on conditions that already carry years-long diagnostic delays. The Women’s Health Initiative, the landmark 30-year federal study of women’s health, had its funding cut last year too.
“What we’ve seen is just a massive devaluation of women. Research is just a piece of it.” — Dr. Kristin Lyerly, OB/GYN
ON THE FEED
Fibermaxxing Is Everywhere. Here’s What’s Actually Worth Knowing.
First it was protein. Now it’s fiber. “Fibermaxxing” has taken over TikTok, grocery aisles, and earnings calls. PepsiCo’s CEO called fiber “the next protein.” And for once, the wellness world has landed on something the science actually supports.
Over 90% of women don’t meet the recommended 25 grams daily. The evidence is solid: better gut health, blood sugar regulation, and reduced cancer risk. Fiber also naturally triggers the same appetite-suppressing hormone targeted by Ozempic. And through the gut-brain axis, higher fiber intake is consistently linked to lower rates of depression and anxiety. Women who eat the most ultra-processed foods had a 49% higher risk of depression than those who didn’t.
The urgency: colorectal cancer is now the leading cause of cancer death in adults under 50, with rates accelerating fastest in younger women. Fiber’s protective effect here is one of the most consistently supported findings in nutritional science. This is more than a trend. It’s a prevention conversation.
The caveat is the “maxxing” part. Going from 15 to 60 grams overnight causes bloating and digestive distress. Diversity beats volume. Whole foods beat supplements. And the food industry is slapping fiber labels on products with no business being called healthy.
Fiber has earned its moment. The products riding its coattails haven’t.
Soft Life vs. Rise and Grind: The Wellness Debate That Won’t Let Women Rest
Your feed is running two campaigns. One says build, push, earn it. At the gym, in your career, in your relationships, and everything in between. The other says slow down, protect your peace, take your time, do less. The algorithm wants you to pick a side. The most grounded women aren’t.
The real skill isn’t choosing between ambition and rest. It’s knowing when to deploy each one. Hard work, career building, pushing your limits, these have real value. So does recovery, stillness, and protecting your energy. The women who are doing this well aren’t living in one camp. They’re moving between both in waves, grinding when the season calls for it, resting without guilt when the body and mind demand it. Knowing the difference is the work.
Neither soft nor hard is a permanent identity. The question worth asking isn’t which one you want to embody, it’s which one you need right now.
THIS WEEK’S SELECTION
Rhode Caffeine Reset — $38 Rhode’s first-ever face mask: Caffeine, peptides, and a warming sensation that depuffs and sculpts in 10 minutes flat.
Brandefy Vitamin C + E + Ferulic Serum — $55 15% pure L-Ascorbic Acid, 0.5% Ferulic Acid, Vitamin E — clinical-grade, dermatologist-approved, made in the USA.
Knix Dream Shorts — $25 The product that ended women’s relationship with overnight pads. Absorbency up to 11 tampons, PFAS-free, buttery soft — and they actually look good.
CurrentBody LED Hair Growth Helmet — $859 FDA-cleared. Clinically proven. 123% increase in hair growth rate in 12 weeks. 10 minutes a day for the hormonal hair loss conversation women have been having in private for years.
The Productivity Method Planner — ~$35 For the women doing both — building something and protecting their energy. Grace Beverly’s viral framework for women who refuse to choose between ambition and balance